

1 **The herpes simplex virus type I deamidase enhances propagation but is**
2 **dispensable for retrograde axonal transport into the nervous system**

3
4
5
6 Austin M. Stults and Gregory A. Smith*

7
8 Department of Microbiology-Immunology, Northwestern University Feinberg
9 School of Medicine, Chicago, Illinois, United States of America

10
11
12
13
14 *Corresponding author:

15
16 Gregory A. Smith, Ph.D.
17 Professor of Microbiology-Immunology
18 Northwestern University Feinberg School of Medicine
19 303 E. Chicago Ave.
20 Chicago, IL 60611

21
22 Phone: (312) 503-3745

23
24 Email: g-smith3@northwestern.edu

25
26
27
28
29
30
31 Abstract = 98 words

32 Manuscript = 3767

33
34
35 **Keywords:** herpesvirus, HSV-1, pUL37, deamidase, axon, transport,
36 neuroinvasion

37

38 **ABSTRACT**

39 Upon replication in mucosal epithelia and transmission to nerve endings, capsids
40 of herpes simplex virus type 1 (HSV-1) travel retrograde within axons to
41 peripheral ganglia where life-long latent infections are established. A capsid-
42 bound tegument protein, pUL37, is an essential effector of retrograde axonal
43 transport and also houses a deamidase activity that antagonizes innate immune
44 signaling. In this report, we examined whether the deamidase of HSV-1 pUL37
45 contributes to the neuroinvasive retrograde axonal transport mechanism. We
46 conclude that neuroinvasion is enhanced by the deamidase, but the critical
47 contribution of pUL37 to retrograde axonal transport functions independently of
48 this activity.

49

50 **IMPORTANCE**

51 Herpes simplex virus type 1 invades the nervous system by entering nerve
52 endings and sustaining long-distance retrograde axonal transport to reach
53 neuronal nuclei in ganglia of the peripheral nervous system. The incoming viral
54 particle carries a deamidase activity on its surface that antagonizes antiviral
55 responses. We examined the contribution of the deamidase to the hallmark
56 neuroinvasive property of this virus.

57

58 **INTRODUCTION**

59 Mammalian viruses of the alpha-herpesvirinae subfamily initially infect a mucosal
60 epithelium and then transmit to innervating sensory and autonomic nerve
61 terminals (1). Virus-mediated fusion into axon terminals results in the deposition
62 of the capsid and tegument proteins into the cytosol, with the majority of
63 tegument proteins dissociating from the capsid. However, at least three tegument
64 proteins, pUL36, pUL37, and pUS3, remain capsid bound (2-5). The pUL36
65 tegument protein directly binds to the pUL25 component of the capsid surface (6-
66 9), and tethers pUL37, pUS3, as well as the host dynein/dynactin microtubule
67 motor, to the capsid (10-13). Each of the capsid-bound tegument proteins has a
68 distinct enzymatic activity: pUL36 houses a deubiquitinase in its amino terminus

69 (14, 15), pUL37 houses a deamidase in its carboxyl terminus (16), and pUS3 is a
70 serine-threonine protein kinase (17). Of these enzymes, only the pUL36
71 deubiquitinase is reported to contribute to the neuroinvasive property of these
72 viruses (18, 19). Nevertheless, pUL37 is a critical component of the
73 neuroinvasive apparatus (20), with an amino-terminal region essential for the
74 delivery of incoming capsids to the neural soma by sustaining dynein-based
75 microtubule transport in axons (21, 22).

76

77 The herpes simplex virus type 1 (HSV-1) pUL37 deamidase antagonizes innate
78 cytosolic sensors including retinoid-acid inducible gene-I (RIG-I) and cyclic GMP-
79 AMP synthase (cGAS) and is an important virulence determinant following
80 peritoneal injection into mice (16, 23). In this report, we examine whether the
81 deamidase specifically promotes HSV-1 invasion of the nervous system.

82

83 RESULTS

84

85 **Confirmation of attenuated interferon suppression during infection with**
86 **HSV-1 encoding a mutated deamidase.** Zhao et al. previously identified two
87 cysteines in HSV-1 pUL37, C819 and C850, as critical for catalytic deamidation
88 of RIG-I *in vitro*, with C819 serving as the catalytic site (16). In the current study,
89 we intended to mutate the catalytic site in pseudorabies virus (PRV) and HSV-1,
90 but we noted that neuroinvasive herpesviruses within the varicellovirus genus of
91 the alpha-herpesvirinae subfamily lack the catalytic cysteine (Fig. 1). Therefore, a
92 cysteine-to-serine change was introduced at C819 in HSV-1 strain F that
93 mimicked the design of the previously characterized catalytic mutant (16). A
94 second HSV-1 mutant was produced encoding C850S. Neither mutant was
95 impaired for pUL37 expression during infection (Fig. 2A). The C819S catalytic
96 mutant triggered 3-fold increased interferon beta expression relative to the wild
97 type upon infection of normal human dermal fibroblasts (NHDF), consistent with
98 reports that the deamidase antagonizes interferon signaling (Fig. 2B) (16, 23).
99 Repair of the C819S mutant (C819S>C) restored the wild-type phenotype.

100 Unexpectedly, HSV-1 encoding C850S was not defective for interferon
101 suppression even though the residue was previously reported to support
102 deamidase activity (16). The reason for this discrepancy was not clear, although
103 we note that the previous study examined the C850S mutant during transient
104 expression and did not examine the phenotype in the context of HSV-1 (16, 23).

105

106 **The pUL37 deamidase supports HSV-1 spread in culture.** HSV-1 propagation
107 kinetics were unaffected by either cysteine mutation (Fig. 3A); however, the
108 C819S mutation reduced the spread of HSV-1 by 24% in primary fibroblasts and
109 in Vero cells (Fig. 3B). To investigate the defect further, a recombinant of HSV-1
110 was produced encoding a CMV immediate-early promoter driving expression of
111 the tdTomato fluorophore fused to a nuclear localization signal. Vero cells were
112 infected at MOI 5 and harvested from 4-12 hpi to quantify the number of
113 fluorescent cells by flow cytometry (Fig. 3C). A reduction in viral gene expression
114 kinetics was observed for the C819S mutant virus, which reached $61.1 \pm 0.6\%$ of
115 cells reporting at 12 hpi, compared to $89.7 \pm 0.9\%$ and $89.4 \pm 1.4\%$ for the wild-
116 type and repair viruses, respectively. Because this result was not predicted by
117 the single-step propagation results that were assessed at MOI 10 (Fig. 3A), Vero
118 cells were infected at MOI 1, 5, and 10 and analyzed by flow cytometry at 8 and
119 24 hpi. The results indicated that the C819S defect was MOI dependent, with the
120 greatest impact observed for MOI 1 and no defect at MOI 10 (Fig. 3C, right).

121

122 **The pUL37 deamidase supports HSV-1 propagation in the mouse cornea
123 and neuroinvasion.** Mice were ocularly infected with the wild-type and C819S
124 viruses following corneal scarification to monitor propagation in the mucosa (tear
125 film) and invasion of the peripheral nervous system (trigeminal ganglia; TG).
126 Sampling of tear films by eye swab demonstrated that the C819S mutant and
127 repair both expanded in the mucosa during the first 20 hpi and then retracted.
128 However, the mutant expanded more slowly and to a lesser degree than the
129 repair virus and retracted faster (Fig. 4A). The reduced propagation in the
130 corneal mucosa correlated to decreased invasion of the TG (Fig. 4B). The wild-

131 type virus consistently invaded the TG from the cornea, whereas invasion by the
132 C819S mutant was stochastic. Several animals infected with C819S lacked
133 detectable plaque-forming units in the TG but possessed viral DNA, consistent
134 with the establishment of a dormant infection. The C819S repaired virus
135 (C819S>C) and the C850S mutant virus were indistinguishable from wild type
136 (Fig. 4C). To determine if the animals producing wild-type yields of the C819S
137 mutant in the TG were the result of spontaneous reversion during infection, the
138 plaque diameter of one such recovered virus was measured and found to be
139 consistent with the C819S phenotype (Fig. 4D, left). This isolate was also
140 confirmed to encode the C819S mutation (Fig. 4D, right).

141

142 **Retrograde axonal transport is not dependent on the pUL37 deamidase.** To
143 test whether mutation of the deamidase had an effect on retrograde axonal
144 transport, capsid transport dynamics were recorded within axons of primary
145 sensory neurons during the first hour post infection. Mutation of either C819 or
146 C850 had no significant impact on the directionality of capsid trafficking in axons
147 (Fig. 5A), the average number of stops and reversals displayed by individual
148 capsids (Fig. 5B), or the velocities and lengths of continuous retrograde runs
149 (Fig. 5C). The distribution of retrograde velocities of each virus was consistently
150 Gaussian ($R^2 \geq 0.99$ for each) and retrograde travel distances were accurately fit
151 as decaying exponentials ($R^2 \geq 0.91$ for each), which is consistent with the
152 processive motion of wild-type HSV-1 (5). Furthermore, delivery of capsids to the
153 nuclear rims of primary sensory neurons was not notably impacted by either
154 cysteine mutation (Fig. 5D). Collectively, these results indicate that the
155 deamidase indirectly promotes neuroinvasion by enhancing HSV-1 propagation
156 in peripheral tissues but does not directly contribute to retrograde axonal
157 transport and delivery to neural soma in sensory ganglia.

158

159 **DISCUSSION**

160

161 Viruses belonging to the simplexvirus and varicellovirus genres of the alpha-
162 herpesvirinae subfamily are noted for their proficient neuroinvasive properties
163 that result in the delivery of viral genomes to nuclei of peripheral ganglia neurons
164 where latent infections are established and maintained. Upon initial exposure
165 virus propagation within peripheral tissues, typically a mucosal epithelium, is
166 required for robust transmission into the nervous system, presumably by
167 increasing the number of viral particles encountering axon terminals at sites of
168 innervation (24, 25). At least two viral proteins directly support the neuroinvasive
169 mechanism. The pUL36 large tegument protein promotes transmission from
170 epithelial tissues to nerve endings and subsequently tethers capsids delivered
171 into the cytosol of axon terminals to the dynein/dynactin microtubule motor
172 complex to drive retrograde axonal transport to sensory ganglia (12, 18). The
173 pUL37 tegument protein sustains dynein-based microtubule transport by
174 restraining opposing plus-end motion (22). Consistent with these roles, pUL36
175 and pUL37 remain attached to capsids upon entry into cells (2, 3, 5, 26), with
176 pUL36 bound directly to the capsid surface (7, 9, 27, 28) and pUL37 bound to
177 pUL36 (10, 11, 29) such that pUL36 tethers pUL37 to the capsid (13).
178 Understanding how the pUL36 and pUL37 tegument proteins mediate
179 neuroinvasion is foundational to developing vectors for neural gene delivery and
180 vaccination.

181 The HSV-1 pUL37 tegument protein was recently found to house a
182 deamidase activity that uses the cellular immune effectors, RIG-I and cGAS, as
183 substrates to antagonize interferon-based antiviral responses (16, 23). The
184 deamidase also supports HSV-1 dissemination into the brain following
185 intraperitoneal challenge of mice, such that HSV-1 encoding a pUL37 C819S
186 catalytic site mutation is incapable of transmitting to the brain from the
187 peritoneum unless animals are knocked out for cGAS (23). This raises the
188 question of whether the deamidase supports propagation in the periphery that
189 indirectly enhances neuroinvasion, or if it also directly contributes to the
190 neuroinvasive process. The latter possibility is compelling given that the pUL37
191 deamidase is anchored on the capsid surface during axonal trafficking (2, 5, 26).

192 In this report, we examined whether neuroinvasion is dependent on the
193 deamidase using the mouse ocular model, which parallels the natural route of
194 HSV-1 infection: inoculation of a mucosal site and subsequent retrograde axonal
195 transport to the trigeminal ganglion of the peripheral nervous system. A pUL37
196 C819S mutant of HSV-1 strain F was produced to mimic the previously reported
197 catalytic mutant and was confirmed to fail to antagonize interferon expression
198 (16, 23). In mice, the C819S mutant displayed reduced propagation in the
199 periphery that correlated to reduced neuroinvasion and production of recoverable
200 virus from the trigeminal ganglion. The decreased propagation *in vivo* correlated
201 to decreased propagation in culture, with the C819S mutant showing: (1) an
202 increased dependence on multiplicity of infection to efficiently infect Vero cells,
203 and (2) a decreased capacity to spread cell-to-cell in the plaque assay.
204 Unexpectedly, the plaque deficit was noted in primary human fibroblasts as well
205 as Vero cells, the latter of which are interferon deficient (30-32). The plaque
206 results in Vero cells indicates that the pUL37 deamidase does more than
207 antagonize interferon responses, or alternatively that RIG-I and cGAS trigger
208 antiviral activities independently of interferon production.

209 Despite the propagation defects in culture and in mice, the C819S mutant
210 was competent to invade the peripheral nervous system, and the capacity of the
211 mutant to promote retrograde axonal transport in primary cultured sensory
212 neurons was unimpaired. These findings raise the question of why the
213 deamidase is housed in a capsid-bound tegument protein that is a critical effector
214 of the transport mechanism. While only speculation can be offered on this point,
215 it is noteworthy that the catalytic cysteine is absent from the neuroinvasive
216 herpesviruses belonging to the varicellovirus genus (Fig. 1), suggesting that the
217 deamidase may be absent from varicelloviruses. Nevertheless, representative
218 members of these two neuroinvasive genera (HSV-1, simplexvirus; PRV,
219 varicellovirus) engage in retrograde axonal transport dynamics that are
220 indistinguishable from one another, which could indicate that the deamidase is a
221 recent evolutionary adaptation of the simplexviruses and not a fundamental
222 component of the neuroinvasive apparatus (5). In this regard HSV-1 also

223 encodes an extended carboxyl terminus on pUL37 that modulates TRAF6
224 signaling (33), which is also absent from PRV. Together, these results
225 demonstrate a role for the pUL37 deamidase in HSV-1 propagation and spread
226 that is not directly required for retrograde axonal transport and invasion of the
227 peripheral nervous system.

228

229 **MATERIALS AND METHODS**

230

231 **Sequences and alignment.** Predicted amino acid sequences of pUL37
232 homologs were aligned using the ClustalW alignment tool in MacVector.
233 GenBank accession numbers used were: GU734771 (herpes simplex virus type
234 1; HSV1), NC_001798 (herpes simplex virus type 2; HSV2), YP_009011024
235 (panine alphaherpesvirus 3; PaHV3), NP_851897 (cercopithecine
236 alphaherpesvirus 1; CeHV1), YP_164480 (cercopithecine alphaherpesvirus 2;
237 CeHV2), BAP00716 (fruit bat alphaherpesvirus 1; FrBHV1), YP_009361900
238 (ateline alphaherpesvirus 1; AtHV1), YP_443884 (papiine alphaherpesvirus 2;
239 PaHV2), YP_009227270 (macropodid alphaherpesvirus 1; MaHV1),
240 YP_003933802 (saimiriine alphaherpesvirus 1; SHV1), YP_009230167 (leporid
241 alphaherpesvirus 4; LHV4), JF797217 (pseudorabies virus; PRV), AJ004801
242 (bovine herpesvirus 1; BHV1), NC_005261 (bovine herpesvirus 5; BHV5),
243 YP_053068 (equid herpesvirus 1; EHV1), YP_009054926 (equid herpesvirus 3;
244 EHV3), NP_045240 (equid herpesvirus 4; EHV4), YP_006273002 (equid
245 herpesvirus 8; EHV8), YP_002333504 (equid herpesvirus 9; EHV9),
246 YP_009252247 (Canid alphaherpesvirus 1; CHV1), ALJ85051 (felid herpesvirus
247 1; FHV1), NP_077436 (cercopithecine alphaherpesvirus 9; CeHV9), NC_001348
248 (varicella-zoster virus; VZV), ASW27069 (beluga whale alphaherpesvirus 1;
249 BWHV1).

250

251 **Recombinant HSV-1 production.** All HSV-1 was derived from an infectious
252 clone of HSV-1 strain F (34). A variant encoding an immediate-early gene
253 reporter, HSVF-GS3217, was produced to monitor viral gene expression as an

254 indication of viral genome delivery to nuclei. To make HSVF-GS3217, an En
255 Passant template plasmid, pEP-CMV>tdTomato-NLS-in>pA, was first produced
256 by modifying a CMV-driven eGFP cassette from pEGFP-N1 (Clontech), such that
257 the CMV immediate early promoter was partially duplicated with an iscei::kan
258 cassette inserted between the duplicated sequences. The entire merodiploid
259 expression cassette was PCR amplified and the resulting linear dsDNA product
260 was transformed into GS1783 bacteria harboring the full-length HSV-1 strain F
261 infectious clone (35). Lambda red recombination was used to insert the product
262 into the HSV-1 US5 gene (encodes the gJ glycoprotein), and the kan cassette
263 was subsequently removed by a second round of lambda red recombination
264 following digestion with the IScel homing enzyme. Missense mutations (Table 1)
265 were also introduced into the infectious clones by En Passant mutagenesis using
266 primers listed in Table 2.

267

268 **Cell lines and HSV-1 propagation.** Vero (African green monkey kidney
269 epithelial, ATCC), Vero-CRE cells expressing Cre recombinase, and PK15 (pig
270 kidney epithelial, ATCC) cells were grown in DMEM (Dulbecco's Modified Eagle
271 Medium, Invitrogen) supplemented with 10% BGS (bovine growth serum, RMBI).
272 Normal human dermal fibroblasts (NHDFs) were generously provided by Derek
273 Walsh and grown in DMEM supplemented with 10% FBS (fetal bovine serum,
274 Gemini Bioproducts). Cells were tested regularly for mycobacterium
275 contamination using the Plasmotest kit (Invivogen) and authenticated by the
276 source. BGS levels were reduced to 2% during and after infection. HSV-1 strains
277 were produced by electroporation of infectious clones into Vero cells using an
278 ECM630 electroporation system (BTX Instrument Division, Harvard Apparatus).
279 Cells were pulsed once with the following settings: 220V, 950 μ F, 0 Ω . Serum
280 levels were reduced to 2% BGS approximately 12 h after electroporation. Virus
281 was harvested at a time at which 100% cells displayed pronounced cytopathic
282 effect (CPE) (typically 5 days post electroporation). Initial viral harvests were
283 subsequently passaged through Vero-Cre cells to excise the bacterial artificial
284 chromosome vector from the viral genome (36).

285

286 **Single-step growth curve and plaque assays.** Vero cells seeded in 6-well
287 plates were infected at a multiplicity of infection (MOI) of 10. After 1 h,
288 unabsorbed virus was inactivated with 1 ml of citrate buffer (pH 3.0), and cells
289 were washed and incubated in 2 ml of DMEM supplemented with 2% BGS at
290 37°C, 5% CO₂. At 2, 5, 8, 12, 24, and 30 hours post infection, HSV-1 was
291 harvested from Vero cells and supernatants. Titers were determined by plaque
292 assay on Vero cells overlaid with 2 ml methocel media (DMEM supplemented
293 with 2% BGS and 10mg/ml methyl cellulose) and allowed to expand for five days.
294 Images of at least 30 isolated plaques from each infection were acquired with a
295 Nikon Eclipse TE2000-U inverted microscope fitted with a 0.30 numerical
296 aperture (NA) 4 x objective and RFP filter set. To determine the plaque diameter,
297 the average of two orthogonal diameter measurements was calculated for each
298 plaque using ImageJ software. Plaque diameters were expressed as a
299 percentage of the diameter of wild-type HSV-1, which was always measured in
300 parallel. Data sets were plotted using GraphPad Prism 7 (GraphPad Software
301 Inc).

302

303 **Primary neuronal culture.** Dorsal root ganglia (DRG) from embryonic chicks
304 (E8-E10) were cultured on poly-DL-ornithine- and laminin-treated coverslips in 2
305 ml of F12 media (Invitrogen) containing nutrient mix: 0.08 g/ml bovine serum
306 albumin fraction V powder (VWR), 0.4 mg/ml crystalline bovine pancreas insulin
307 (Sigma-Aldrich), 0.4 µg/ml sodium selenite (VWR), 4 µg/ml avian transferrin
308 (Intercell Technology) and 5 ng/ml nerve growth factor (NGF; Sigma-Aldrich).
309 DRGs from embryonic rats (E18) (Neuromics) were cultured as described above
310 and supplemented with human holo-transferrin (Sigma-Aldrich). A single explant
311 was cultured on each cover slip for 2 to 3 days and infected with 5 x 10⁷ PFU/ml
312 of virus for five minutes. Cover slips were subsequently mounted to a glass cover
313 slide and time-lapse imaging of mCherry emissions was achieved by automated
314 sequential capture using 150 ms exposures between 0.5-1.0 hpi for retrograde
315 transport analysis, and 3.0-4.0 hpi for nuclear rim formation.

316

317 **Fluorescence microscopy and image analysis.** Virus transport dynamics were
318 monitored in primary DRG explants. Explants were infected in 2 ml of F12 media
319 with 5×10^7 PFU/ml of HSV-1 (WT and mutants) from 0.5-1.0 hpi. Time-lapse
320 images were captured using an inverted wide-field Nikon Eclipse TE2000-U
321 microscope fitted with a 60x/1.4 NA objective and a Cascade:512 electron-
322 multiplying charge-coupled device (EM-CCD; Photometrics). The microscope
323 was housed in a 37° environmental box (In Vivo Scientific). Moving particles were
324 detected by time-lapse fluorescence microscopy in the red-fluorescence channel
325 at 10 frames per second (continued 100 ms exposures) for 150 frames. Particle
326 trajectories were traced in the 150 frame time-lapse image stacks using a multi-
327 line tool with a width of 20 pixels and average background subtraction, and a
328 kymograph was produced using the MetaMorph software package (Molecular
329 Devices). The multi-line tool was again employed to trace kymograph paths, and
330 the fraction of time that a particle was stopped, moving anterograde, or moving
331 retrograde was calculated for each particle. Forward distance and forward
332 velocity for each particle were also measured and filtered for distances >0.5
333 microns to control for random diffusion of virions. Graphs were created in
334 GraphPad Prism 7.

335

336 **Ethics statement.** All procedures confirmed to NIH guidelines for work with
337 laboratory animals and were approved by the Institutional Animal Care and Use
338 Committee of Northwestern University (IS00003334). Fertilized chicken eggs
339 were obtained from Sunnyside, Inc. and tissue was harvested between
340 embryonic day 8 and 10.

341

342 ***In vivo* methods.** Intraocular HSV-1 infections of BALB/c mice (9 week old;
343 Jackson Lab) were carried out in animals anesthetized with an intraperitoneal
344 injection of ketamine (86.98 mg/kg) and xylazine (13.04 mg/kg) mixture. Each
345 cornea was lightly abraded 10 times in a crosshatched pattern with a 25-gauge
346 needle, and 1×10^6 PFU of HSV-1 was administered to the cornea surface. Prior

347 to infection, the virus stock was sonicated and centrifuged for 2 min at 300 x g to
348 remove cell debris. Tears containing shed virus were collected by proptosing
349 each eye and swabbing with a damp cotton applicator three times in a circular
350 pattern around the eye. Two independent experiments were performed to collect
351 virus within the tear films of infected mice at 12, 16, and 20 hpi, and at 24, 48,
352 and 72 hpi. At the indicated day post infection each trigeminal ganglion was
353 removed and individually homogenized in 1 ml DMEM, sonicated, and stored at -
354 80°C. Titers of recovered HSV-1 from tissues were determined on Vero cells as
355 described above.

356

357 **Preparation of cell lysates and Western blotting.** Vero cells were seeded in a
358 6-well plate and infected at a MOI of 10. After 1 hour the inoculum was aspirated
359 and replaced with DMEM + 2% BGS. After 18 hours the cells were washed once
360 with ice cold 1X PBS and harvested in cold RIPA lysis buffer (50 mM Tris, pH 8,
361 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
362 sulfate) supplemented with protease inhibitors (2.5 mM sodium fluoride, 1 mM
363 sodium orthovanadate, 0.5 mM phenylmethylsulphonyl fluoride, 100 I of protease
364 inhibitor cocktail [Sigma]). Lysates were rotated for 30 minutes, sonicated for
365 three 1.5-s pulses, and rotated for an additional 30 min. Lysates were then spun
366 at 13,000 X g for 20 min, and the supernatants were harvested. 2.5% of the
367 supernatant from each lysate was mixed with 2X final sample buffer (62.5 mM
368 Tris [pH 6.8], 2% SDS, 10% glycerol, 0.01% bromophenol blue) supplemented
369 with 50 mM dithiothreitol (DTT) and loaded onto an acrylamide gel for SDS-
370 PAGE. Blots were probed with an antibody raised against HSV-1 pUL37 (HA108,
371 Virusys; diluted 1:3300) and an antibody raised against HSV-1 VP5 (diluted
372 1:2000; courtesy of Frank Jenkins).

373

374 **Genomic Sequencing.** Viral DNA was isolated from stocks of infected Vero cells
375 (titers ranging from 10^7 - 10^8 PFU/ml) using the PureLink Viral RNA/DNA kit
376 (Invitrogen). Isolated viral DNA was used in a standard PCR reaction to amplify
377 the genomic region encoding the deamidase, which was then purified using the

378 Wizard Gel and PCR Clean-Up System (Promega) and submitted to a third party
379 for sequencing.

380

381 **Quantitative PCR on mouse tissue.** DNA was isolated from homogenized
382 trigeminal ganglia using the DNeasy Blood and Tissue Kit (Qiagen). The final
383 DNA concentration was diluted to 10 ng/μl. Each sample was run in triplicate
384 using a 10 μl reaction volume consisting of: 5 μl of CyberGreen Mastermix
385 (Roche), 0.5 μl forward primer (30 μM), 0.5 μl reverse primer (30 μM), 1.5 μl
386 water, and 2.5 μl of DNA. Run settings were 95°C for 10 min, 50 cycles of 95°C
387 for 15 sec, and 60°C for 30 sec. The forward and reverse primer sequences
388 were: HSV-1 UL35 Fwd: GTCTTGGCCACCAATAACTC; HSV-1 UL35 Rev:
389 GGGTAAACGTGTTGTTTTCG; mGAPDH Fwd: GATGGGTGTGAACCACGAG,
390 and mGAPDH Rev: GTGATGGCATGGACTGTGG. Fold change was calculated
391 using the $2^{\Delta\Delta Ct}$ method.

392

393 **Real-time quantitative PCR.** RNA was isolated on ice from infected cells using
394 the PureLink RNA Mini kit (Invitrogen). The final RNA concentration was diluted
395 to 10 ng/μl and mixed with 10 μl of master mix to form cDNA. Run settings were
396 25°C for 10 minutes, 37°C for 2 hours, and 85°C for 5 minutes. cDNA was diluted
397 1:5 with RNase-free water and used in a qPCR reaction as described above. The
398 forward and reverse primers for each gene were previously published [Feng 2]:
399 Human Ifnb Fwd: AGGACAGGATGAACTTTGAC; Human Ifnb Rev:
400 TGATAGACATTAGCCAGGAG; Human B-Actin Fwd:
401 CTGGCACCCAGCACAATG; Human B-actin Rev:
402 GCCGATCCACACGGAGTACT. Fold change was calculated using the $2^{\Delta\Delta Ct}$
403 method.

404

405 **Viral gene expression.** Vero cells were seeded to 100% confluency in six well
406 plates and infected at a MOI 5 on ice for one hour to synchronize the infection of
407 each virus. After one hour the cells were shifted to 37°C, 5% CO₂. At the
408 indicated times, cells were harvested, washed once with PBS, and fixed with 4%

409 paraformaldehyde for 4-16 hours. Cells were then subject to fluorescence-
410 activated cell sorting to quantify the percent of cells containing positive tdTomato
411 signal. 20,000 cells were counted for each sample with each sample prepared in
412 triplicate.

413

414 **ACKNOWLEDGEMENTS**

415 We thank Sarah Antinone and Kevin Bohannon for their assistance in producing
416 pEP-CMV>tdTomato-NLS-in>pA and HSVF-GS3217, and Derek Walsh for
417 generously providing NHDF cells. Flow cytometry services were performed at the
418 Robert H. Lurie Comprehensive Cancer Center Flow Cytometry Core, and
419 sequencing services were performed at the Northwestern University Genomics
420 Core Facility.

421

422 **FUNDING INFORMATION**

423 This work was funded by the National Institute of Allergy and Infectious
424 Diseases, including the efforts of Austin M. Stults and Gregory A. Smith (R01
425 AI056346).

426 **REFERENCES**

427

- 428 1. Smith G. 2012. Herpesvirus Transport to the Nervous System and Back
429 Again. *Annu Rev Microbiol* 66:153-76.
- 430 2. Luxton GW, Haverlock S, Collier KE, Antinone SE, Pincetic A, Smith GA.
431 2005. Targeting of herpesvirus capsid transport in axons is coupled to
432 association with specific sets of tegument proteins. *Proc Natl Acad Sci U*
433 *S A* 102:5832-7.
- 434 3. Granzow H, Klupp BG, Mettenleiter TC. 2005. Entry of pseudorabies virus:
435 an immunogold-labeling study. *J Virol* 79:3200-5.
- 436 4. Collier KE, Smith GA. 2008. Two viral kinases are required for sustained
437 long distance axon transport of a neuroinvasive herpesvirus. *Traffic*
438 9:1458-70.
- 439 5. Antinone SE, Smith GA. 2010. Retrograde axon transport of herpes
440 simplex virus and pseudorabies virus: a live-cell comparative analysis. *J*
441 *Virol* 84:1504-12.
- 442 6. Uetz P, Dong YA, Zeretzke C, Atzler C, Baiker A, Berger B, Rajagopala
443 SV, Roupelieva M, Rose D, Fossum E, Haas J. 2006. Herpesviral protein
444 networks and their interaction with the human proteome. *Science* 311:239-
445 42.
- 446 7. Collier KE, Lee JI, Ueda A, Smith GA. 2007. The capsid and tegument of
447 the alpha herpesviruses are linked by an interaction between the UL25
448 and VP1/2 proteins. *J Virol* 81:11790-7.
- 449 8. Pasdeloup D, Blondel D, Isidro AL, Rixon FJ. 2009. Herpesvirus Capsid
450 Association To The Nuclear Pore Complex And Viral DNA Release
451 Involve The Nucleoporin CAN/Nup214 And The Capsid Protein pUL25. *J*
452 *Virol* 83:6610-23.
- 453 9. Liu Y-T, Jiang J, Bohannon KP, Dai X, Luxton GW, Hui WH, Bi G-Q, Smith
454 GA, Zhou ZH. 2017. A pUL25 dimer interfaces the pseudorabies virus
455 capsid and tegument. *J Gen Virol* 98:2837-49.
- 456 10. Klupp BG, Fuchs W, Granzow H, Nixdorf R, Mettenleiter TC. 2002.
457 Pseudorabies Virus UL36 Tegument Protein Physically Interacts with the
458 UL37 Protein. *J Virol* 76:3065-71.
- 459 11. Vittone V, Diefenbach E, Triffett D, Douglas MW, Cunningham AL,
460 Diefenbach RJ. 2005. Determination of interactions between tegument
461 proteins of herpes simplex virus type 1. *J Virol* 79:9566-71.
- 462 12. Zaichick SV, Bohannon KP, Hughes A, Sollars PJ, Pickard GE, Smith GA.
463 2013. The herpesvirus VP1/2 protein is an effector of dynein-mediated
464 capsid transport and neuroinvasion. *Cell Host Microbe* 13:193-203.
- 465 13. Daniel GR, Pegg CE, Smith GA. 2018. Dissecting the herpesvirus
466 architecture by targeted proteolysis. *J Virol* 92:e00738-18.
- 467 14. Kattenhorn LM, Korbel GA, Kessler BM, Spooner E, Ploegh HL. 2005. A
468 deubiquitinating enzyme encoded by HSV-1 belongs to a family of
469 cysteine proteases that is conserved across the family Herpesviridae. *Mol*
470 *Cell* 19:547-57.

- 471 15. Schlieker C, Korbel GA, Kattenhorn LM, Ploegh HL. 2005. A
472 Deubiquitinating Activity Is Conserved in the Large Tegument Protein of
473 the Herpesviridae. *J Virol* 79:15582-15585.
- 474 16. Zhao J, Zeng Y, Xu S, Chen J, Shen G, Yu C, Knipe D, Yuan W, Peng J,
475 Xu W, Zhang C, Xia Z, Feng P. 2016. A viral deamidase targets the
476 helicase domain of RIG-I to block RNA-induced activation. *Cell Host*
477 *Microbe* 20:770-784.
- 478 17. McGeoch DJ, Davison AJ. 1986. Alphaherpesviruses possess a gene
479 homologous to the protein kinase gene family of eukaryotes and
480 retroviruses. *Nucleic Acids Res* 14:1765-77.
- 481 18. Huffmaster NJ, Sollars PJ, Richards AL, Pickard GE, Smith GA. 2015.
482 Dynamic ubiquitination drives herpesvirus neuroinvasion. *Proc Natl Acad*
483 *Sci U S A* 112:12818-23.
- 484 19. Böttcher S, Maresch C, Granzow H, Klupp BG, Teifke JP, Mettenleiter TC.
485 2008. Mutagenesis of the active-site cysteine in the ubiquitin-specific
486 protease contained in large tegument protein pUL36 of pseudorabies virus
487 impairs viral replication in vitro and neuroinvasion in vivo. *J Virol* 82:6009-
488 16.
- 489 20. Klopffleisch R, Teifke JP, Fuchs W, Kopp M, Klupp BG, Mettenleiter TC.
490 2004. Influence of tegument proteins of pseudorabies virus on
491 neuroinvasion and transneuronal spread in the nervous system of adult
492 mice after intranasal inoculation. *J Virol* 78:2956-66.
- 493 21. Pitts JD, Klabis J, Richards AL, Smith GA, Heldwein EE. 2014. Crystal
494 structure of the herpesvirus inner tegument protein UL37 supports its
495 essential role in control of viral trafficking. *J Virol* 88:5462-73.
- 496 22. Richards AL, Sollars PJ, Pitts JD, Stults AM, Heldwein EE, Pickard GE,
497 Smith GA. 2017. The pUL37 tegument protein guides alpha-herpesvirus
498 retrograde axonal transport to promote neuroinvasion. *PLoS Pathog*
499 13:e1006741.
- 500 23. Zhang J, Zhao J, Xu S, Li J, He S, Zeng Y, Xie L, Xie N, Liu T, Lee K, Seo
501 GJ, Chen L, Stabell AC, Xia Z, Sawyer SL, Jung J, Huang C, Feng P.
502 2018. Species-Specific Deamidation of cGAS by Herpes Simplex Virus
503 UL37 Protein Facilitates Viral Replication. *Cell Host Microbe* 24:234-248
504 e5.
- 505 24. Thompson RL, Sawtell NM. 2000. Replication of herpes simplex virus type
506 1 within trigeminal ganglia is required for high frequency but not high viral
507 genome copy number latency. *J Virol* 74:965-74.
- 508 25. Katz JP, Bodin ET, Coen DM. 1990. Quantitative polymerase chain
509 reaction analysis of herpes simplex virus DNA in ganglia of mice infected
510 with replication-incompetent mutants. *J Virol* 64:4288-95.
- 511 26. Aggarwal A, Miranda-Saksena M, Boadle RA, Kelly BJ, Diefenbach RJ,
512 Alam W, Cunningham AL. 2012. Ultrastructural visualization of individual
513 tegument protein dissociation during entry of herpes simplex virus 1 into
514 human and rat dorsal root ganglion neurons. *J Virol* 86:6123-37.

- 515 27. Cardone G, Newcomb WW, Cheng N, Wingfield PT, Trus BL, Brown JC,
516 Steven AC. 2012. The UL36 tegument protein of herpes simplex virus 1
517 has a composite binding site at the capsid vertices. *J Virol* 86:4058-64.
- 518 28. Dai X, Zhou ZH. 2018. Structure of the herpes simplex virus 1 capsid with
519 associated tegument protein complexes. *Science* 360:eaa07298.
- 520 29. Mijatov B, Cunningham AL, Diefenbach RJ. 2007. Residues F593 and
521 E596 of HSV-1 tegument protein pUL36 (VP1/2) mediate binding of
522 tegument protein pUL37. *Virology* 368:26-31.
- 523 30. Desmyter J, Melnick JL, Rawls WE. 1968. Defectiveness of interferon
524 production and of rubella virus interference in a line of African green
525 monkey kidney cells (Vero). *J Virol* 2:955-61.
- 526 31. Emeny JM, Morgan MJ. 1979. Regulation of the interferon system:
527 evidence that Vero cells have a genetic defect in interferon production. *J*
528 *Gen Virol* 43:247-52.
- 529 32. Mosca JD, Pitha PM. 1986. Transcriptional and posttranscriptional
530 regulation of exogenous human beta interferon gene in simian cells
531 defective in interferon synthesis. *Mol Cell Biol* 6:2279-83.
- 532 33. Liu X, Fitzgerald K, Kurt-Jones E, Finberg R, Knipe DM. 2008.
533 Herpesvirus tegument protein activates NF-kappaB signaling through the
534 TRAF6 adaptor protein. *Proc Natl Acad Sci U S A* 105:11335-9.
- 535 34. Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y. 2003.
536 Construction of an excisable bacterial artificial chromosome containing a
537 full-length infectious clone of herpes simplex virus type 1: viruses
538 reconstituted from the clone exhibit wild-type properties in vitro and in
539 vivo. *J Virol* 77:1382-91.
- 540 35. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a
541 two step markerless red recombination system. *Methods Mol Biol*
542 634:421-30.
- 543 36. Gierasch WW, Zimmerman DL, Ward SL, Vanheyningen TK, Romine JD,
544 Leib DA. 2006. Construction and characterization of bacterial artificial
545 chromosomes containing HSV-1 strains 17 and KOS. *J Virol Methods*
546 135:197-206.
- 547

548 **FIGURE LEGENDS**

549

550 **FIG 1: The pUL37 residues C819 and C850 are conserved within the**
551 **simplexvirus genera.** Alignment of the deamidase region of pUL37 across 24
552 members of the alpha-herpesvirinae subfamily spanning the simplexvirus and
553 varicellovirus genera. The HSV-1 residues C819 and C850 are circled in blue.

554

555 **FIG 2: The catalytic residue of the pUL37 deamidase is required to**
556 **antagonize interferon beta mRNA expression.** (A) Western blot analysis of
557 pUL37 expression in Vero cells at 18 hpi (MOI 10). (B) RT-qPCR analysis of
558 interferon beta mRNA levels in NHDFs 5 hpi. Fold change is quantified relative to
559 mock-infected cells. Error bars are s.d. (**, $p < 0.01$ based on ordinary one-way
560 ANOVA followed by Dunnett's multiple comparisons test).

561

562 **FIG 3: The pUL37 deamidase supports infection at low multiplicity and viral**
563 **spread.** (A) HSV-1 single-step propagation kinetics were determined by counting
564 plaque-forming units harvested from Vero cells (Cells) and the corresponding
565 supernatant (Sups) at the times indicated. (B) HSV-1 plaque sizes on NHDF cells
566 at 32 hpi (left) and Vero cells at 72 hpi (right) were compiled across three
567 independent experiments and plotted as a percentage of wild type. (C) Vero cells
568 infected with HSV-1 encoding a tdTomato-NLS reporter at MOI 5 (left) or at the
569 designated MOI (right) were harvested at the indicated times and scored for red
570 fluorescence by flow cytometry. Error bars are s.d. (****, $p < 0.0001$ based on
571 ordinary one-way ANOVA followed by Dunnett's multiple comparisons test).

572

573 **FIG 4: Mutation of pUL37 C819 delays invasion of the trigeminal ganglia**
574 **upon ocular inoculation of mice.** Mice were infected with HSV-1 encoding the
575 pUL25/mCherry capsid fusion on both eyes following dual corneal scarification.
576 (A) Tear film was sampled by swabbing each eye at the indicated times post
577 infection. The data is a compilation of two experiments: four animals were used
578 for the 12-20 hpi samples, and five animals were used for the 24-72 hpi samples.

579 (B) Infectious HSV-1 (black bars) and HSV-1 DNA (grey bars) were recovered
580 from individual TGs harvested and homogenized at 4 dpi. HSV-1 DNA levels
581 were measured by qPCR and expressed as a fold change relative to mock-
582 infected. Samples from each set of infections are presented in order of the titer
583 recovered. (C) Titers were determined from TGs of additional mice. The mean
584 titer of each virus is indicated by a red bar (10 TGs per virus from 5 mice; pairs of
585 TGs from same animal are shaded equivalently). (D) Recovered C819S virus
586 from the TG indicated in panel B (†) was examined for plaque diameter (left) and
587 by sequence analysis (right). (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; based on
588 two-tailed unpaired t test).

589

590 **FIG 5: The pUL37 deamidase is dispensable for retrograde axonal**
591 **transport.** Primary sensory neurons were infected with HSV-1 encoding the
592 pUL25/mCherry fusion and the indicated pUL37 allele, and transport dynamics in
593 axons were monitored for the first hour post infection. (A) Fraction of time
594 capsids moved in the retrograde direction, anterograde direction, or were
595 stopped. (B) Average number of stops and reversals exhibited by capsids. (C)
596 Distributions of forward run velocities and forward run distances of individual
597 capsids in axons during the first hour post infection. (D) Representative images
598 of capsids at nuclear rims of rat DRGs at 3-4 hpi. For panels A-D, more than
599 thirty capsids were analyzed per experiment across three biological replicates.

TABLE 1: Recombinant viruses

Strain	Fluorescent reporter	Mutant	Titer (PFU/ml)
HSVF-GS4553 ^a	pUL25/mCherry	-	8.55 x 10 ⁷
HSVF-GS6801	pUL25/mCherry	pUL37 C819S	9.17 x 10 ⁷
HSVF-GS6769	pUL25/mCherry	pUL37 C850S	9.33 x 10 ⁷
HSVF-GS7016	pUL25/mCherry	pUL37 C819S>C	1.15 x 10 ⁸
HSVF-GS3217	gJ::CMV>NLS-tdTomato>pA	-	1.20 x 10 ⁸
HSVF-GS6958	gJ::CMV>NLS-tdTomato>pA	pUL37 C819S	1.73 x 10 ⁸
HSVF-GS6959	gJ::CMV>NLS-tdTomato>pA	pUL37 C850S	1.80 x 10 ⁸
HSVF-GS7065	gJ::CMV>NLS-tdTomato>pA	pUL37 C819S>C	1.23 x 10 ⁸

^a Previously published [Huffmaster 2015].

TABLE 2: Primers used for En Passant mutagenesis

Strains	Primer pair ^a
HSVF-GS6801 HSVF-GS6958	5' GGGCCCTGGCCGCCCCGAGGCCATGGGGGACGCGGTGAGTCAGT ACTCCAGCATGTATCACGAC AGGATGACGACGATAAGTAGGG 5' CGCGAGGGACGCGACCAGCGCGCGCTTGGCGTCGTGATACATGC TGGAGTACTGACTCACCGCC CAACCAATTAACCAATTCTGATTAG
HSVF-GS6769 HSVF-GS6959	5' AGCCTGCGTTCCGTCATCACCGAAACCACGGCGCACCTGGGCGT GTCCGACGAGCTGGCGGCC AGGATGACGACGATAAGTAGGG 5' GGCCAGCACGTTGTCCTCGTGCACACCTGGGCCCGCCAGCTCGT CGGACACGCCAGGTGCGCC CAACCAATTAACCAATTCTGATTAG
HSVF-GS7016 HSVF-GS7065	5' GGGCCCTGGCCGCCCCGAGGCCATGGGGGACGCGGTGAGTCAGT ACTGCAGCATGTATCACGAC AGGATGACGACGATAAGTAGGG 5' CGCGAGGGACGCGACCAGCGCGCGCTTGGCGTCGTGATACATGC TGCAGTACTGACTCACCGCC CAACCAATTAACCAATTCTGATTAG

^a Sequences in bold share homology to the pEP-KanS2 template plasmid.




FIGURE 1: The pUL37 residues C819 and C850 are conserved within the simplexvirus genera. Alignment of the deamidase region of pUL37 across 24 members of the alpha-herpesviruses subfamily spanning the simplexvirus and varicellovirus genera. The HSV-1 residues C819 and C850 are circled in blue.




FIGURE 2: The catalytic residue of the pUL37 deamidase is required to antagonize interferon beta mRNA expression.

(A) Western blot analysis of pUL37 expression in Vero cells at 18 hpi (MOI 10).

(B) RT-qPCR analysis of interferon beta mRNA levels in NHDFs at 5 hpi. Fold change is quantified relative to mock-infected cells. Error bars are s.d. (**, $p < 0.01$ based on ordinary one-way ANOVA followed by Dunnett's multiple comparisons test).




FIGURE 3: The pUL37 deamidase supports infection at low multiplicity and viral spread.

(A) HSV-1 single-step propagation kinetics were determined by counting plaque-forming units harvested from Vero cells (Cells) and the corresponding supernatant (Sups) at the times indicated.

(B) HSV-1 plaque sizes on NHDF cells at 32 hpi (left) or Vero cells at 72 hpi (right) were compiled across three independent experiments and plotted as a percentage of wild type.

(C) Vero cells infected with HSV-1 encoding a tdTomato-NLS reporter at MOI 5 (left) or at the designated MOI (right) were harvested at the indicated times and scored for red fluorescence by flow cytometry. Error bars are s.d. (****, $p < 0.0001$ based on ordinary one-way ANOVA followed by Dunnett's multiple comparisons test).




FIGURE 4: Mutation of pUL37 C819 delays invasion of the trigeminal ganglia upon ocular inoculation of mice. Mice were infected with HSV-1 encoding the pUL25/mCherry capsid fusion on both eyes following dual corneal scarification.

(A) Tear film was sampled by swabbing each eye at the indicated times post infection. The data is a compilation of two experiments: four animals were used for the 12-20 hpi samples, and five animals were used for the 24-72 hpi samples.

(B) Infectious HSV-1 (black bars) and HSV-1 DNA (grey bars) were recovered from individual TGs harvested and homogenized at 4 dpi. HSV-1 DNA levels were measured by qPCR and expressed as a fold change relative to mock-infected. Samples from each set of infections are presented in order of the titer recovered.

(C) Titers were determined from TGs of additional mice. The mean titer of each virus is indicated by a red bar (10 TGs per virus from 5 mice; pairs of TGs from same animal are shaded equivalently).

(D) Recovered C819S virus from the TG indicated in panel B (†) was examined for plaque diameter (left) and by sequence analysis (right). (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; based on two-tailed unpaired t test).




FIGURE 5: The pUL37 deamidase is dispensable for retrograde axonal transport. Primary sensory neurons were infected with HSV-1 encoding the pUL25/mCherry fusion and the indicated pUL37 allele, and transport dynamics in axons were monitored for the first hour post infection.

(A) Fraction of time capsids moved in the retrograde direction, anterograde direction, or were stopped.

(B) Average number of stops and reversals exhibited by capsids.

(C) Distributions of forward run velocities and forward run distances of individual capsids in axons during the first hour post infection.

(D) Representative images of capsids at nuclear rims of rat DRGs at 3-4 hpi.

For panels A-C, more than thirty capsids were analyzed per experiment across three biological replicates.